Quality of life, its early change and retention in MMT program in Iran: Evidence for policymakers and service providers

Life Science Journal

Volumn 9, Issue 3, 2012, Pages 2633-2638

  Rouhani, Samad ^a,b   Kheirkhah, Farzan ^c   Salarieh, Iraj ^c   Abedi, Saleh ^c  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c BABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

MMT; Policymaker; Quality of life; Retention

Indexed keywords

EID: 84874868025     PISSN: 10978135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Ardebili, E. M., Salehi, S., Gharai, B., Daneshamuz, B., Nassr, M., Ghalebandi, M. F. (2006). A household study on the prevalence of substance misuse in Tehran: The need for other methods to estimate the prevalence. Iranian Journal of Psychiatry. 1: 158-161.
2. Arrindell, W.A., Ettema, J.H.M. (1986). SCL-90: Handleiding bij een Multidimensionele Psychopathologie Indicator. Swets & Zeitlinger, Lisse (Manual for a multidimensional psychopathology indicator).
3. Ball, J.C., Lange, W.R., Myers, C.P., Friedman, S.R. (1988). Reducing the risk of AIDS through methadone maintenance treatment. Journal of Health Social Behavior. 29: 214-226.
4. Bell, J., Burrell, T., Indig, D., Gilmour, S. (2006). Cycling in and out of treatment: Participation in methadone treatment in NSW, 1990-2002. Drug and Alcohol Dependence. 81: 55-61.
5. Calabrese, J. (2007). Iran's war on drugs: Holding the line? The Middle East Institute Policy Brief. No.3. December. Washington.
6. Darke, S., Ross, J., Teesson, M., Ali, R., Cooke, R., Ritter, A., Lynskey, M. (2005). Factors associated with 12 months continuous heroin abstinence: Findings from the Australian Treatment Outcome Study (ATOS). Journal of Substance Abuse Treatment. 28: 255-263.
7. Dolan, D. Salimi, S. Nassirimanesh, B. Mohsenifar, S. Allsop, D. Azarakhsh, M. (2012). Six-month follow-up of Iranian women in methadone treatment: drug use, social functioning, crime, and HIV and HCV seroincidence. Substance Abuse and Rehabilitation. 3(Suppl 1): 37-43.
8. Goodarzi, F., Karrari, P., Eizadi-Mood, N., Mehrpour, O., Misagh, R., Setude, S., Amrollahi, M. (2011). Epidemiology of drug abuse (Chronic Intoxication) and its related factors in a MMT clinic in Shiraz, southern Iran. Iranian Journal of Toxicology. 4(4): 377-380.
9. EuroQol Group. (1990). EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 16: 199-208.
10. Evans, E., Li, L., Hser, Y. (2008). Treatment entry barriers among California's Proposition 36 offenders. Journal of Substance Abuse Treatment, 35: 410-418.
11. Habrat, B., Chmielewska, K., Baran-Furga, H., Keszycka, B., Taracha, E. (2002). Subjective Quality of Life in opiate-dependent patients before admission after six months and one-year participation in methadone program. Przegl. Lek. 59(4-5): 351-4.
12. Joe, G. W., Simpson, D. D., Broome, K. M. (1999). Retention and patient engagement models for different treatment modalities in DATOS. Drug and Alcohol Dependence. 57: 113-125.
13. Karow, A., Reimer, J., Schafer, I., Krausz, M., Haasen, C., Verthein, U. (2010). Quality of life under maintenance treatment with heroin versus methadone in patients with opioid dependence. Drug and Alcohol Dependence. 112: 209-215.
14. Kelly, S.M., O'Grady, K.E., Mitchell, S.G., Brown, B.S., Schwartz, R.P. (2011). Predictors of methadone treatment retention from a multi-site study: a survival analysis. Drug and Alcohol Dependence. 117(2-3): 170-175
15. Kokkevi, A., Hartgers, C. (1995). EuropASI: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. European Addiction Research.1: 208-210.
16. Lieberman, D., & Massey, S. (2008). Pathways to change: The effect of a Web application on treatment interest. American Journal on Addictions. 17: 265-270.
17. Maremmani, I., Pani, P.P., Pacini, M., Perugi, G. (2007). Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. Journal of Substance Abuse Treatment. 33: 91-98.
18. Marsden, J., Gossop, M., Stewart, D., Best, D., Farrell, M., Lehmann, P., Edwards, C., Strang, J. (1998). The Maudsley Addiction Profile (MAP): A brief instrument for assessing treatment outcome. Addiction. 93: 1857-1867.
19. McLellan, A.T., Alterman, A.I., Metzger, D.S., Grissom, G.R., Woody, G.E., Luborsky, L., O'Brien, C.P. (1997). Similarity of outcome predictors across opiate cocaine and alcohol treatments: role of treatment services. Journal of Consulting and Clinical Psychology. 62: 1141-1158.
20. Miller, P.G., Miller, W.R. (2009). What should we be aiming for in the treatment of addiction? Addiction. 104: 685-686.
21. Mokri, A. (2002). Brief overview of the status of drug abuse in Iran. Archives of Iranian Medicine. 5 (3): 184-190.
22. Morral, A. R., Belding, M. A., Iguchi M. Y. (1999). Identifying methadone maintenance clients at risk for poor treatment response: pretreatment and early progress indicators. Drug and Alcohol Dependence. 55: 25-33.
23. Padaiga, Z. Subata, E. Vanagas, G. (2007). Outpatient methadone maintenance treatment program quality of life and health of opioiddependent persons in Lithuania. Medicina (Kaunas). 43(3): 235-241.
24. Ponizovsky, A.M., Grinshpoon, A. (2007). Quality of life among heroin users on buprenorphine versus methadone maintenance. American Journal of Drug and Alcohol Abuse. 33: 631-642.
25. Rouhani, S., Salarieh, I., Abedi, S., Kheirkhah, F. (2012). Impact of Methadone Maintenance Treatment on the quality of life of opioid dependents in city of Babol. Journal of Mazandaran University of Medical Sciences. 22 (87): 47-55.
26. Rumah Sakit Ketergantungan Obat (RSKO). (2008). Laporan Kegiatan Tahunan (Annual Report) 2007. Jakarta: RSKO.
27. Sarasvita, R., Tonkin, A., Utomo, B., Ali, R. (2012). Predictive factors for treatment retention in methadone programs in Indonesia. Journal of Substance Abuse Treatment. 42: 239-246.
28. Shekarchizadeh, H., Ekhtiari, H., Khami, R. M., Virtanen, I. J. (2012). Patterns of pre-treatment drug abuse, drug treatment history and characteristics of addicts in methadone maintenance treatment in Iran. Harm Reduction Journal. 9: 18. Published online 2012 June 7. doi: 10.1186/1477-7517-9-18
29. Simpson, D. D., Joe, G. W. (1997). Strategies for improving methadone treatment process and outcomes. Journal of Drug Issues. 27: 239-261.
30. Simpson, D. D., Joe, G. W. (2004). A longitudinal evaluation of treatment engagement and recovery stages. Journal of substance abuse treatment. 27: 89-97.
31. Torrens, M., Domingo-Salvany, A., Alonso, J., Castillo, C., San, L. (1999). Methadone and quality of life. Lancet. 353. 1101.
32. UNODC. World Drug Report 2008 (United Nations Publication, Sales No. E.08. XI.1). 2008.
33. Ventegodt, S., Merrick, J. (2003). Psychoactive drugs and quality of life. Scientific World Journal. 3: 694-706.
34. Villafranca, S.W., McKellar, J.D., Trafton, J.A., Humphreys, K. (2006). Predictors of retention in methadone programs: a signal detection analysis. Drug and Alcohol Dependence. 83: 218-224.
35. Wang, P. W., Wu, H.C., Yen, C. N., Yeh, Y. C., Chung, K. S., Chang, H. C., Yen, C. F. (2012). Change in quality of life and its predictors in heroin users receiving methadone maintenance treatment in Taiwan: an 18-month follow-up study. American Journal of Drug and Alcohol Abuse. 38(3): 213-9.
36. Zanden, B. P., Dijkgraaf, M. G. W., Blanken, P., de Borgie, C. A., van Ree, J. M., Brink, W. (2006). Validity of the EQ-5D as a generic health outcome instrument in a heroin-dependent population. Drug and Alcohol Dependence. 82: 111-118.